BACKGROUND Major depressive disorder(MDD)is a significant psychiatric condition that poses a serious threat to human life,primarily due to its association with suicidal behavior.The single nucleotide polymorphism rs37...BACKGROUND Major depressive disorder(MDD)is a significant psychiatric condition that poses a serious threat to human life,primarily due to its association with suicidal behavior.The single nucleotide polymorphism rs372369000 is a risk locus for MDD and is located within the B4GALT6 gene.However,the biological and pathological implications of B4GALT6 in the brain concerning MDD remain unclear.AIM To reveal the biological and pathological significance of B4GALT6 in the brain and MDD.METHODS An inflammation-associated depression mouse model was developed by treating mice with lipopolysaccharides.B4GALT6-like immunoreactivity distribution and expression level was examined throughout the brain.RESULTS B4GALT6-like immunoreactivity increased in the hippocampus,PrL,and the visual cortex V1 region of MDD mice.This elevation varied across different brain subregions and cell types.Specifically,pathological alterations in B4GALT6-like immunoreactivity were observed in CA1 microglia,CA2 neurons,CA3 microglia and neurons,as well as V1 microglia and astrocytes.These changes correlated with the pathology of depression.CONCLUSION Although the neuropathological role of B4GALT6 in the brain remains to be fully characterized,B4GALT6 may be a potential therapeutic target for MDD.展开更多
目的:舒芬太尼镇痛效果存在个体差异。本研究旨在评价CYP2B6(CPB6)*4和OPRM1基因多态性对膝关节镜下患者术后舒芬太尼静脉镇痛效应的影响。方法:选择择期腰麻硬膜外联合麻醉下行膝关节镜前交叉韧带重建术患者210例,患者术后使用静脉镇...目的:舒芬太尼镇痛效果存在个体差异。本研究旨在评价CYP2B6(CPB6)*4和OPRM1基因多态性对膝关节镜下患者术后舒芬太尼静脉镇痛效应的影响。方法:选择择期腰麻硬膜外联合麻醉下行膝关节镜前交叉韧带重建术患者210例,患者术后使用静脉镇痛泵。术前采集2 mL静脉血置入抗凝管,留作检测CPB6*4和OPRM1的基因多态性,根据CPB6*4和OPRM1基因的不同基因组将患者分为A/A组、G/A组、G/G组、T/T组和C/T组,观察不同基因组患者术后疼痛数字评分(Numerical Rating Scale,NRS)、病人自控镇痛(patient controlled analgesia,PCA)按压次数、舒芬太尼用量、术后开始出现疼痛的时间以及术后不良事件的发生率。结果:共纳入202例患者,CPB6*4rs2279343中A/A组76例,G/A组110例,G/G组16例;OPRM1 rs73568641中T/T组194例,C/T组8例。与G/A组和A/A组相比,G/G组术后7 d NRS均降低(均P<0.05);术后1和3 d NRS、PCA按压次数、舒芬太尼用量、术后开始疼痛的时间、术后不良反应、术后住院时间及术后3个月慢性疼痛的发生率差异均无统计学意义(均P>0.05)。与T/T组相比,C/T组术后1和3 d NRS、PCA按压次数、舒芬太尼用量增加,差异均有统计学意义(均P<0.05);术后7 d NRS、术后开始疼痛的时间、术后不良反应、术后住院时间及术后3个月慢性疼痛的发生率比较差异均无统计学意义(均P>0.05)。结论:CPB6*4和OPRM1基因多态性是引起膝关节镜患者术后舒芬太尼静脉镇痛个体化差异的遗传因素。展开更多
基金Supported by Hunan Provincial Natural Science Foundation of China,No.2025JJ80473 and No.2025JJ80484the Institute of Hospital Management,National Health Commission of China,Major Project,No.SZ2024HL021.
文摘BACKGROUND Major depressive disorder(MDD)is a significant psychiatric condition that poses a serious threat to human life,primarily due to its association with suicidal behavior.The single nucleotide polymorphism rs372369000 is a risk locus for MDD and is located within the B4GALT6 gene.However,the biological and pathological implications of B4GALT6 in the brain concerning MDD remain unclear.AIM To reveal the biological and pathological significance of B4GALT6 in the brain and MDD.METHODS An inflammation-associated depression mouse model was developed by treating mice with lipopolysaccharides.B4GALT6-like immunoreactivity distribution and expression level was examined throughout the brain.RESULTS B4GALT6-like immunoreactivity increased in the hippocampus,PrL,and the visual cortex V1 region of MDD mice.This elevation varied across different brain subregions and cell types.Specifically,pathological alterations in B4GALT6-like immunoreactivity were observed in CA1 microglia,CA2 neurons,CA3 microglia and neurons,as well as V1 microglia and astrocytes.These changes correlated with the pathology of depression.CONCLUSION Although the neuropathological role of B4GALT6 in the brain remains to be fully characterized,B4GALT6 may be a potential therapeutic target for MDD.
文摘目的:舒芬太尼镇痛效果存在个体差异。本研究旨在评价CYP2B6(CPB6)*4和OPRM1基因多态性对膝关节镜下患者术后舒芬太尼静脉镇痛效应的影响。方法:选择择期腰麻硬膜外联合麻醉下行膝关节镜前交叉韧带重建术患者210例,患者术后使用静脉镇痛泵。术前采集2 mL静脉血置入抗凝管,留作检测CPB6*4和OPRM1的基因多态性,根据CPB6*4和OPRM1基因的不同基因组将患者分为A/A组、G/A组、G/G组、T/T组和C/T组,观察不同基因组患者术后疼痛数字评分(Numerical Rating Scale,NRS)、病人自控镇痛(patient controlled analgesia,PCA)按压次数、舒芬太尼用量、术后开始出现疼痛的时间以及术后不良事件的发生率。结果:共纳入202例患者,CPB6*4rs2279343中A/A组76例,G/A组110例,G/G组16例;OPRM1 rs73568641中T/T组194例,C/T组8例。与G/A组和A/A组相比,G/G组术后7 d NRS均降低(均P<0.05);术后1和3 d NRS、PCA按压次数、舒芬太尼用量、术后开始疼痛的时间、术后不良反应、术后住院时间及术后3个月慢性疼痛的发生率差异均无统计学意义(均P>0.05)。与T/T组相比,C/T组术后1和3 d NRS、PCA按压次数、舒芬太尼用量增加,差异均有统计学意义(均P<0.05);术后7 d NRS、术后开始疼痛的时间、术后不良反应、术后住院时间及术后3个月慢性疼痛的发生率比较差异均无统计学意义(均P>0.05)。结论:CPB6*4和OPRM1基因多态性是引起膝关节镜患者术后舒芬太尼静脉镇痛个体化差异的遗传因素。
